Skip to main content
. 2016 Aug 12;8(33):54136–54148. doi: 10.18632/oncotarget.11250

Figure 2. Fractalkine-induced cell migration is mediated by ICAM-1 expression in osteosarcoma.

Figure 2

A. MG63 cells were treated with various concentrations of fractalkine for 24 h. Total RNA was extracted, and ICAM-1 mRNA expression was measured using qPCR. B. The osteosarcoma cell lines MG63 and U2OS were incubated with 10 ng/mL fractalkine for the indicated times. ICAM-1 mRNA expression was measured using qPCR. C. MG63 cells were treated as indicated (Figure 2A), and total protein was collected. VCAM-1 and ICAM-1 expression levels were assessed using Western blotting. D. MG63 cells were treated as indicated (Figure 2B), and total protein was collected. The VCAM-1 and ICAM-1 expression levels were assessed using Western blotting. E. MG63 cells were treated with the indicated concentrations of fractalkine for 24 h. The cells were stained with the ICAM-1 antibody and FITC-conjugated secondary antibody, and ICAM-1 expression was assessed using flow cytometric analysis. F. MG63 cells were transfected with ICAM-1 or negative siRNA (control) for 24 h and subsequently incubated with fractalkine (10 ng/mL) for 24 h. Cell migration ability was analyzed using the Transwell assay. The upper panel shows the expression of ICAM-1 in siRNA-transfected cells. Results are expressed as the mean ± SEM of triplicate samples. *P < 0.05 compared with the control group and #P < 0.05 compared with the fractalkine-treated group.